EWTXRegulation•prnewswire•
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Sentiment:Negative (10)
Summary
BOULDER, Colo., Aug. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on July...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by prnewswire